April 09, 2025

FDA Approves Nivolumab With Ipilimumab for Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer

The FDA approved the combination of a PD-1 inhibitor and a CTLA-4 inhibitor for patients with unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer ...

The ASCO Post

February 15, 2024

Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?

Circulating tumor DNA may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from receiving adjuvant chemotherapy. The re...

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

August 02, 2023

Gastrointestinal Symptoms May Be Prevalent in Geriatric Female Colorectal Cancer Survivors

About 80% of geriatric female colorectal cancer survivors may experience a range of gastrointestinal symptoms years after receiving a diagnosis and treatment for their tumors, according to a recent st...

The ASCO Post

December 04, 2023

Consuming Navy Beans May Improve Gut Health, Regulate Immune and Inflammatory Processes in Colorectal Cancer Survivors

Researchers investigated whether the regular consumption of navy beans could help improve the gut microbiome of colorectal cancer survivors.

The ASCO Post

February 13, 2025

Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer

The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E...

The ASCO Post

June 23, 2023

Expert Point of View: Lisa Newman, MD, MPH, FACS, FASCO

Dr. Lisa Newman emphasizes the critical relevance of including diverse populations in clinical genomic profiling for colorectal cancer, shedding light on potential missed opportunities in homogeneous population studies.

The ASCO Post

January 24, 2024

Study Finds Majority of Patients With Lynch Syndrome Are Not Using Aspirin to Reduce Risk of Colon Cancer

In the PREVENTLynch study, investigators assessed the prevalence of aspirin use as a protective measure against colon cancer among patients with Lynch syndrome.

The ASCO Post

March 28, 2024

Stage III Colorectal Cancer: Association of Immunoscore With Disease-Free Survival

In an analysis of two trials (SCOT and IDEA-HORG), investigators identified the predictive value of Immunoscore for disease-free survival in patients with stage III colorectal cancer treated with adju...

The ASCO Post